Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Group B Meningococcal 8570 HOPS-G NOMV Vaccine
- Development stage
- Phase 1
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The Group B Meningococcal 8570 HOPS-G NOMV Vaccine is an investigational vaccine candidate designed to protect against Neisseria meningitidis serogroup B. It is based on native outer membrane vesicles (NOMVs) derived from a genetically modified strain of N. meningitidis known as 8570 HOPS-G1. The vaccine leverages the immunogenic properties of outer membrane vesicles, which contain multiple surface antigens including PorA proteins and other conserved bacterial components that stimulate a protective immune response. This approach aims to overcome the challenge posed by the poor immunogenicity and autoantigenic nature of the group B polysaccharide capsule by targeting protein antigens instead[1][4][7]. The primary indication for this vaccine is prevention of invasive disease caused by N. meningitidis serogroup B.
- Other names
- Group B Meningococcal 8570 HOPS-G NOMV VaccineNeisseria meningitidis group B OMV vaccine (strain 8570 HOPS-G)
02
Targets
Neisseria meningitidis serogroup B outer membrane antigens
Beyond the preview
Go deeper on Group B Meningococcal 8570 HOPS-G NOMV Vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Group B Meningococcal 8570 HOPS-G NOMV Vaccine.